Synergistic in vitro Interactions between (22S,23S)-3beta-Bromo-5alpha,22,23-Trihydroxystigmastan-6-one and Acyclovir or Foscarnet against Herpes simplex Virus Type 1

LAURA B. TALARICO; VIVIANA CASTILLA; JAVIER A. RAMIREZ; LYDIA R. GALAGOVSKY; MÓNICA B. WACHSMAN

CHEMOTHERAPY

Karger

Año: 2006 vol. 52 p. 38 - 42

0009-3157

The replication of herpes simplex virus (HSV) type 1 in Vero cells is inhibited in the presence of (22S,23S)-3-bromo-5,22,23-trihydroxystigmastan-6-one (6b), a synthetic brassinosteroid derivative. Since a late step of virus multiplication is hindered by 6b, we performed studies of drug-drug combination with acyclovir (ACV) and foscarnet (FOS). It was determined that 6b would act synergistically with low concentrations of ACV and moderate concentrations of FOS against HSV. The best drug combination tested in this study resulted in an increase of 29.3 and 47.2% in antiviral activity for ACV (0.036 µM) and FOS (37.5 µM) in the presence of 14.8 and 6.9 µM of 6b, respectively.